BioVaxys and Sona Nanotech Enter Research Collaboration | PR Newswire [Video]

, /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys“) and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) (“Sona“) announce today that they have entered into a Research Agreement (“Agreement”) to collaborate on the development of new cancer therapeutics based on BioVaxys’ DPX™ Immune Educating Platform (“DPX”) in combination with Sona’s Targeted Hyperthermia Therapy™ (“THT”), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona’s proprietary biocompatible Gold Nanorod (“GNR”) technology which elicits a strong immune response.

Carman Giacomantonio, MD, Chief Medical Officer (“CMO”) for Sona Nanotech Inc., commented, “Looking beyond our approaching first-in-human Early Feasibility Study clinical trial for our THT cancer therapy, Sona continues to conduct research to build our pipeline of programs to fully exploit the potential of our GNR technology platform. To …